

Pancreatic Cancer

REFERENCES

- Abiaka CD, Al-Awadi FM et al. Plasma micronutrient antioxidant in cancer patients. *Cancer Detect Prev* . 2001;25(3):245-53.
- Ahn WS, Yoo J et al. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. *Eur J Cancer Prev* . 2003;12(5):383-90.
- Alarcon de la Lastra C, Barranco MD et al. Mediterranean diet and health: biological importance of olive oil. *Curr Pharm Des* . 2001;7(10):933-50.
- Alcock RA, Dey S et al. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2. *Oncogene* . 2002;21(51):7883-90.
- Alguacil J, Porta M et al. Occupational exposure to dyes, metals, polycyclic aromatic hydrocarbons and other agents and K-ras activation in human exocrine pancreatic cancer. *Int J Cancer* . 2003;107(4):635-41.
- Aller R, de Luis DA et al. Effect of soluble fiber intake in lipid and glucose levels in healthy subjects: a randomized clinical trial. *Diabetes Res Clin Pract* . 2004;65(1):7-11.
- American Cancer Society. Cancer Facts and Figures 2005.2005.
- Anderson KM, Seed T et al. NTBN, a free radical spin trap induces programmed cell death in human pancreatic cancer (PANC-1) cells. *Anticancer Research* . 1998a;18(5A):3213-22.
- Anderson KM, Seed T et al. Five-lipoxygenase inhibitors reduce Panc-1 survival: the mode of cell death and synergism of MK886 with gamma linolenic acid. *Anticancer Res* . 1998b;18(2A):791-800.
- Andren-Sandberg A, Johansson J. Influence of sex hormones on pancreatic cancer. *Int J Pancreatol* . 1990;7(1-3):167-76.
- Ansari MS, Gupta NP. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. *Urol Oncol* . 2004;22(5):415-20.
- Appel MJ, Woutersen RA. Effects of dietary beta-carotene and selenium on initiation and promotion of pancreatic carcinogenesis in azaserine-treated rats. *Carcinogenesis* . 1996;17(7):1411-6.
- Armstrong T, Walters E et al. Deficiencies of micronutrients, altered bowel function, and quality of life during late follow-up after pancreaticoduodenectomy for malignancy. *Pancreatology* . 2002;2(6):528-34.
- Bai J, Sata N et al. Genistein-induced changes in gene expression in Panc 1 cells at physiological concentrations of genistein. *Pancreas* . 2004;29(2):93-8.
- Bai YR, Wu GH et al. Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study. *World J Gastroenterol* . 2003;9(11):2561-4.
- Baker CH, Kedar D et al. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. *Am J Pathol* . 2002a;161(3):929-38.
- Baker CH, Solorzano CC et al. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. *Cancer Res* . 2002b;62(7):1996-2003.
- Banerjee S, Zhang Y et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. *Cancer Res* . 2005;65(19):9064-72.

Barber MD, Fearon KC. Tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia. *Lipids* 2001;36(4):347-51.

Barber MD, McMillan DC et al. Metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish-oil-enriched nutritional supplement. *Clin Sci (Lond)* . 2000;98(4):389-99.

Barber MD, Ross JA et al. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. *Brit J Cancer* . 1999;81(1):80-6.

Bartsch DK, Sina-Frey M et al. CDKN2A germline mutations in familial pancreatic cancer. *Ann Surg* . 2002;23(6):730-7.

Bauer JD, Capra S. Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy-a pilot study. *Support Care Cancer* . 2004; IN PRESS.

Belanger JT. Perillyl alcohol: applications in oncology. *Altern Med Rev* . 1998;3(6):448-57.

Berrington de Gonzalez A, Sweetland S et al. A meta-analysis of obesity and the risk of pancreatic cancer. *British Journal of Cancer* . 2003;89(3):519-23.

Berrozpe G, Schaeffer J et al. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. *Int J Cancer* . 1994;58(2):185-91.

BioDrugs, 2002. Cancer vaccine--antigenics. *BioDrugs* 2002;16(1):72-4.

Bjelakovic G, Nikolova D et al. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. *Lancet* . 2004;364(9441):1219-28.

Blumenthal RD, Hansen HJ et al. Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen). *Cancer Res* . 2005;65(19):8809-17.

Boadas J, Mora J et al. Clinical usefulness of K-ras gene mutation detection and cytology in pancreatic juice in the diagnosis and screening of pancreatic cancer. *Eur J Gastroenterol Hepatol* . 2001 Oct;13(10):1153-9.

Boari C, Montanari FM et al. [Toxic occupational liver diseases. Therapeutic effects of silymarin]. *Minerva Med* . 1981;72(40):2679-88.

Boik J. *Natural Compounds in Cancer Therapy: Promising Nontoxic Antitumor Agents from Plants and Other Natural Sources* . Princeton, MN: Oregon Medical Press; 2001.

Boros LG, Bassilian S et al. Genistein inhibits nonoxidative ribose synthesis in MIA pancreatic adenocarcinoma cells: a new mechanism of controlling tumor growth. *Pancreas* . 2001;22(1):1-7.

Bouvet M, Nardin SR et al. Parathyroid hormone-related protein as a novel tumor marker in pancreatic adenocarcinoma. *Pancreas* . 2002;24(3):284-90.

Braga M, Cristallo M et al. Correction of malnutrition and maldigestion with enzyme supplementation in patients with surgical suppression of exocrine pancreatic function. *Surg Gynecol Obstet* . 1988;167(6):485-92.

Brand R. The diagnosis of pancreatic cancer. *Cancer J* . 2001;7(4):287-97.

Brasiuniene B, Brasiunas V et al. Molecular factors of pancreatic cancer pathogenesis and prognosis. *Medicina (Kaunas)* . 2003;39(7):631-6.

Broitman SA, Wilkinson J et al. Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic "metastases" in vivo. *Adv Exp Med Biol* . 1995;401:111-30.

Bruno MJ, Haverkort EB et al. Maldigestion associated with exocrine pancreatic insufficiency: implications of gastrointestinal physiology and properties of enzyme preparations for a cause-related and patient-tailored treatment. *Am J Gastroenterol* . 1995a;90(9):1383-93.

Bruno MJ, Hoek FJ et al. Simultaneous assessments of metabolic function by cholesteryl-[¹⁴C]octanoate breath test and measurement of plasma p-aminobenzoic acid. *Clin Chem* . 1995b;41(4):599-604.

Buchler P, Gukovskaya AS et al. Prevention of metastatic pancreatic cancer growth in vivo by induction of apoptosis with genistein, a naturally occurring isoflavonoid. *Pancreas* . 2003;26(3):264-73.

Buchler P, Reber HA et al. Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. *Cancer* . 2004;100(1):201-10.

Burke YD, Ayoubi AS et al. Effects of the isoprenoids perillyl alcohol and farnesol on apoptosis biomarkers in pancreatic cancer chemoprevention. *Anticancer Research* . 2002;22(6A):3127-34.

Burns, CP, Halabi, S, et al. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. *Clin Cancer Res* 1999;5(12):3942-7.

Burriss HA3. Objective outcome measures of quality of life. *Oncology (Williston Park)* . 1996;10(11 Suppl):131-5.

Cai J, Jiang WG et al. Inhibition of angiogenic factor- and tumour-induced angiogenesis by gamma linolenic acid. *Prostaglandins Leukot Essent Fatty Acids* . 1999;60(1):21-9.

Caldas C, Hahn SA et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. *Cancer Res* . 1994 Jul 1;54(13):3568-73.

Chen da W, Wei Fei Z et al. Role of enteral immunonutrition in patients with gastric carcinoma undergoing major surgery. *Asian J Surg* . 2005;28(2):121-4.

Chen X, Yano Y et al. Inhibition of farnesyl protein transferase and P21ras membrane association by d-limonene in human pancreas tumor cells in vitro. *Chin Med Sci J* . 1999;14(3):138-44.

Choi YH, Lee WH et al. p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. *Jpn J Cancer Res* . 2000;91(2):164-73.

Chow HH, Cai Y et al. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. *Cancer Epidemiol Biomarkers Prev* . 2001;10(1):53-8.

Chow HH, Cai Y et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. *Clin Cancer Res* . 2003;9(9):3312-9.

Chu J, Lloyd FL et al. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. *Mol Cancer Ther* . 2003;2(1):1-7.

Cleary SP, Gryfe R et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. *J Am Coll Surg* . 2004;198(5):722-31.

Comstock GW, Helzlsouer KJ et al. Prediagnostic serum levels of carotenoids and vitamin E as related to subsequent cancer in Washington County, Maryland. *Am J Clin Nutr* . 1991;53((1 Suppl)):260S-4S.

Corbishley TP, Iqbal MJ et al. Circulating sex steroids and sex hormone binding globulin in pancreatic adenocarcinoma. *Anticancer Res* . 1986;6(2):219-22.

Coss A, Cantor KP et al. Pancreatic cancer and drinking water and dietary sources of nitrate and nitrite. *Am J Epidemiol* . 2004;159(7):693-701.

Cowgill SM, Muscarella P. The genetics of pancreatic cancer. *Am J Surg* . 2003;186(3):279-86.

Crane CH, Mason K et al. Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. *Am J Clin Oncol* . 2003;26(4):81-4.

Crowell PL, Siar AA et al. Antitumorigenic effects of limonene and perillyl alcohol against pancreatic and breast cancer. *Adv Exp Med Biol* . 1996;401:131-6.

Cuendet M, Pezzuto JM. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. *Drug Metabol Drug Interact* . 2000;17(1-4):109-57.

Cullen JJ, Mitros FA et al. Expression of antioxidant enzymes in diseases of the human pancreas: another link between chronic pancreatitis and pancreatic cancer. *Pancreas* . 2003;26(1):23-7.

DeMeo MT. Pancreatic cancer and sugar diabetes. *Nutr Rev* . 2001;59(4):112-5.

Dimagno EP, Reber HA et al. AGA technical review on the epidemiology, diagnosis and treatment of pancreatic ductal adenocarcinoma. *Gastroenterol Clin Biol* . 1999;117:1464-84.

Ding XZ, Tong WG et al. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. *Anticancer Research* . 2000;20(4):2625-31.

Ding XZ, Tong WG et al. Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer. *Pancreatol* . 2001;1(4):291-9.

EI-Metwally TH, Adrian TE. Optimization of treatment conditions for studying the anticancer effects of retinoids using pancreatic adenocarcinoma as a model. *Biochemical & Biophysical Research Communications* . 1999;257(2):596-603.

Ertekin MV, Koc M et al. The effects of oral zinc sulphate during radiotherapy on anti-oxidant enzyme activities in patients with head and neck cancer: a prospective, randomised, placebo-controlled study. *Int J Clin Pract* . 2004;58(7):662-8.

Fearon KC, Falconer JS et al. An open-label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gammalinolenate. *Anticancer Research* . 1996;16(2):867-74.

Ferrari V, Valcamonico F et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. *Cancer Chemother Pharmacol* . 2005;1-6.

Ferreira PR, Fleck JF et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. *Head Neck* . 2004;26(4):313-21.

Ferry DR, Deakin M et al. A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. *Ann Oncol* . 2000;11(9):1165-70.

Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. *Crit Rev Clin Lab Sci* . 2000;37(5):431-502.

Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. *J Nutr* . 2003;133(10):3275S-84S.

Friess H, Wang L et al. Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas. *Ann Surg* . 1999;230(6):767-74.

Fujioka S, Scwabas GM et al. Function of nuclear factor kappaB in pancreatic cancer metastasis. *Clin Cancer Res* . 2003;9(1):346-54.

Gail MH, You WC et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. *Control Clin Trials* . 1998;19(4):352-69.

Ganepola GA, Gritsman AY et al. Are pancreatic tumors hormone dependent?: A case report of unusual, rapidly growing pancreatic tumor during pregnancy, its possible relationship to female sex hormones, and review of the literature. *Am Surg* . 1999;65(2):105-11.

Gansauge F, Ramadani M et al. NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial. *Langenbecks Archives of Surgery* . 2002;386(8):570-4.

Gapstur SM, Gann PH et al. Abnormal glucose metabolism and pancreatic cancer mortality. *JAMA* . 2000;283(19):2552-8.

Garcea G, Dennison AR et al. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy.

Gelb MH, Tamanoi F et al. The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. *Cancer Lett* . 1995;91(2):169-75.

Gescher A. Polyphenolic phytochemicals versus non-steroidal anti-inflammatory drugs: which are better cancer chemopreventive agents? *J Chemother* . 2004;16 Suppl 4:3-6.

Ghadirian P, Lynch HT et al. Epidemiology of pancreatic cancer: an overview. *Cancer Detect Prev* . 2003;27(2):87-93.

Gjertsen MK, Buanes T et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. *Int J Cancer* . 2001;92(3):441-50.

Gjertsen MK, Saeterdal I et al. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes. *J Mol Med* . 2003;81(1):43-50.

Gogos CA, Ginopoulos P et al. Dietary omega-3 fatty polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: A randomized control trial. *Cancer* . 1998;82(2):395-402.

Gold DV, Cardillo T et al. Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4. *Int J Cancer* . 1997;71(4):660-7.

Gold DV, Lew K et al. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. *Int J Cancer* . 1994;57(2):204-10.

Gold DV, Schutsky K et al. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. *Clin Cancer Res* . 2003;9(10 Pt 2):3929S-39S.

Goldstein D, Carroll S et al. Modern management of pancreatic carcinoma. *Intern Med J* . 2004;34(8):475-81.

Gonzalez NJ, Isaacs LL. Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support. *Nutr Cancer* . 1999;33(2):117-24.

Grant AG, McGlashan D et al. A study of pancreatic secretory and intracellular enzymes in pancreatic cancer tissue, other gastrointestinal cancers, normal pancreas and serum. *Clin Chim Acta* . 1978;90(1):75-82.

Grutzmann R, Pilarsky C et al. Systematic isolation of genes differentially expressed in normal and cancerous tissue of the pancreas. *Pancreatology* . 2003;3(2):169-78.

Grzesiak JJ, Clopton P et al. The extracellular matrix differentially regulates the expression of PTHrP and the PTH/PTHrP receptor in FG pancreatic cancer cells. *Pancreas* . 2004;29(2):85-92.

Grzesiak JJ, Smith KC et al. GSK3 and PKB/Akt are associated with integrin-mediated regulation of PTHrP, IL-6 and IL-8 expression in FG pancreatic cancer cells. *Int J Cancer* . 2005;114(4):522-30.

Guo JM, Xiao BX et al. Effects of daidzein on estrogen-receptor-positive and negative pancreatic cancer cells in vitro. *World J Gastroenterol* . 2004;10(6):860-3.

Hansel DE, Ashfaq R et al. A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening and treatment. *Am J Clin Pathol* . 2005;123(1):28-35.

Hardcastle IR, Rowlands MG et al. Inhibition of protein prenylation by metabolites of limonene. *Biochem Pharmacol* . 1999;57(7):801-9.

Heisler T, Towfigh S et al. Peptide YY augments gross inhibition by vitamin E succinate of human pancreatic cancer cell growth. *Journal of Surgical Research* . 2000;88(1):23-5.

Hennig R, Ding XZ et al. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. *American Journal of Pathology* . 2002;161(2):421-8.

Hernaandez J, Syed S et al. The modulation of prostate cancer risk with alpha-tocopherol: a pilot randomized, controlled clinical trial. *J Urol* . 2005;174(2):519-22.

Hidaka H, Ishiko T et al. Curcumin inhibits interleukin 8 production and enhances interleukin 8 receptor expression on the cell surface: impact on human pancreatic carcinoma cell growth by autocrine regulation. *Cancer* . 2002;95(6):1206-14.

Higashi T, Saga T et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) -- usefulness and limitations in "clinical reality". *Ann Nucl Med* . 2003;17(4):261-79.

Hiura A, Tsutsumi M et al. Inhibitory effect of green tea extract on the process of pancreatic carcinogenesis induced by N-nitrosobis-(2-oxypropyl)amine (BOP) and on tumor promotion after transplantation of N-nitrosobis-(2-hydroxypropyl)amine (BHP)-induced pancreatic cancer in Syrian hamsters. *Pancreas* . 1997;15(3):272-7.

Hoos A, Levey DL. Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. *Expert Rev Vaccines* . 2003;2(3):369-79.

Hoppin JA, Tolbert PE et al. Pancreatic cancer and serum organochlorine levels. *Cancer Epidemiol Biomarkers Prev* . 2000;9(2):199-205.

Hotz HG, Hines OJ et al. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. *Surgery* . 2005;137(2):192-9.

Igimi H, Hisatsugu T et al. The use of d-limonene preparation as a dissolving agent of gallstones. *Am J Dig Dis* . 1976;21(11):926-39.

Irigoyen Oyarzabal AM, Amiguet Garcia JA et al. [Tumoral markers and acute-phase reactants in the diagnosis of pancreatic cancer]. *Gastroenterol Hepatol* . 2003;26(10):624-9.

Ito K, Nakazato H et al. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up. *Int J Colorectal Dis* . 2004;19(2):157-64.

Jaffee EM, Abrams R et al. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. *Hum Gene Ther* . 1998;9(13):1951-71.

Jaffee EM, Hruban RH et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. *J Clin Oncol* . 2001;19(1):145-56.

Ji BT, Chow WH et al. Green tea consumption and the risk of pancreatic and colorectal cancers. *Int J Cancer* . 1997;70(3):255-8.

Jia L, Zhang MH et al. Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice. *World J Gastroenterol* . 2005;11(3):447-50.

Jiang XT THZSC. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. *Hepatobiliary Pancreat Dis Int* . 2004;3(3):464-8.

Joshi SS, Kuszynski CA et al. The cellular and molecular basis of health benefits of grape seed proanthocyanidin extract. *Curr Pharm Biotechnol* . 2001;2(2):187-200.

Kairemo KJ, Jekunen AP et al. The effect of lithium gamma-linolenate therapy of pancreatic cancer on perfusion in liver and pancreatic tissues. *Pancreas* . 1998;16(1):105-6.

Karlson J, Borg-Karlson AK et al. Inhibition of tumor cell growth by monoterpenes in vitro: evidence of a Ras-independent mechanism of action. *Anticancer Drugs* . 1996;7(4):422-9.

Katdare M, Osborne MP et al. Inhibition of aberrant proliferation and induction of apoptosis in pre-neoplastic human mammary epithelial cells by natural phytochemicals. *Oncol Rep* . 1998;5(2):311-5.

Kim T. Technology evaluation: Matuzumab, Merck KGaA. *Curr Opin Mol Ther* . 2004;6(1):96-103.

Kim YI. Folate and cancer prevention: a new medical application of folate beyond hyperhomocysteinemia and neural tube defects. *Nutr Rev* . 1999;57(10):314-21.

Kim YI, Baik HW et al. Effects of folate supplementation on two provisional molecular markers of colon cancer: a prospective, randomized trial. *Am J Gastroenterol* . 2001;96(1):184-95.

Kise Y, Yamamura M et al. Inhibitory effect of selenium on hamster pancreatic cancer induction by N'-nitrosobis(2-oxopropyl) amine. *Int J Cancer* . 1990;46(1):95-100.

Klek S, Kulig J et al. The clinical value of parenteral immunonutrition in surgical patients. *Acta Chir Belg* . 2005;105(2):175-9.

Koda K, Miyazaki M et al. A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines. *Int J Oncol* . 2003;23(1):165-72.

Kokawa A, Kondo H et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. *Cancer* . 2001;91(2):333-8.

Konner J, O'Reilly E. Pancreatic cancer: epidemiology, genetics, and approaches to screening. *Oncology* 2002; 16(12): 1615-22, 1631-2; discussion 1632-3, 1637-8.

Korutla L, Cheung JY et al. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. *Carcinogenesis* . 1995;16(8):1741-5.

Kurosaki I, Hatakeyama K. Adjuvant Systemic Chemotherapy with Gemcitabine for Stage IV Pancreatic Cancer: A Preliminary Report of Initial Experience. *Chemotherapy* 2005;51(6):305-10.

La Vecchia C, Negri E. Fats in seasoning and the relationship to pancreatic cancer. *European Journal of Cancer Prevention* . 1997;6(4):370-3.

Lai PB, Ross JA et al. Cell cycle arrest and induction of apoptosis in pancreatic cancer cells exposed to eicosapentaenoic acid in vitro. *British Journal of Cancer* . 1996;74(9):1375-83.

Lamerz R. Role of tumor markers, cytogenetics. *Ann Oncol* . 1999;10(Suppl 4):145-9.

Lei S, Appert HE et al. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. *Int J Pancreatol* . 1995;17(1):15-21.

Levy MJ, Wiersema MJ. Endoscopic ultrasound in the diagnosis and staging of pancreatic cancer. *Oncology (Huntingt)* . 2002;16(1):29-38.

Li D, Jiao L. Molecular epidemiology of pancreatic cancer. *Int J Gastrintest Cancer* . 2003;33(1):3-14.

Li L, Aggarwal BB et al. Nuclear factor-kappaB and IkappaBkinase are constitutively active in human pancreatic cells and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. *Cancer* . 2004;101(10):2351-62.

Li Y, Ahmed F et al. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. *Cancer Res* . 2005;65(15):6934-42.

Li Y, Ellis KL et al. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BXPc-3 pancreatic cancer cell line. *Pancreas* . 2004;28(4):90-5.

Lian F, Li Y et al. p53-independent apoptosis induced by genistein in lung cancer cells. *Nutr Cancer* . 1999;33(2):125-31.

Lian JP, Word B et al. Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3-carbinol (I3C) and genistein. *Anticancer Res* . 2004;24(1):133-7.

Liang YC, Lin-shiau SY et al. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. *J Cell Biochem* . 1997;67(1):55-65.

- Lipton A, Harvey H et al. Gemcitabine/Irinotecan/celecoxib in pancreatic cancer. *Oncology (Williston Park)* . 2004;18(14 Suppl 14):43-5.
- Lowenfels AB, Maisonneuve P. Epidemiologic and etiologic factors of pancreatic cancer. *Hematol Oncol Clin North Am* . 2002;16(1):1-16.
- Lowenfels AB, Maisonneuve P. Epidemiology and prevention of pancreatic cancer. *Jpn J Clin Oncol* . 2004;34(5):238-44.
- Lu ZX, Walker KZ et al. Arabinoxylan fiber, a byproduct of wheat flour processing, reduces the postprandial glucose response in normoglycemic subjects. *Am J Clin Nutr* . 2000;71(5):1123-8.
- Lyn-Cook BD, Rogers T et al. Chemopreventive effects of tea extracts and various components on human pancreatic and prostate tumor cells in vitro. *Nutr Cancer* . 1999a;35(1):80-6.
- Lyn-Cook BD, Rogers T et al. Chemopreventive effects of tea extracts and various components on human pancreatic and prostate tumor cells in vitro. *Nutr Cancer* . 1999b;35(1):80-6.
- Maiti TK, Chatterjee J et al. Effect of green tea polyphenols on angiogenesis induced by an angiogenin-like protein. *Biochem Biophys Res Commun* . 2003;308(1):64-7.
- Masamune A, Kikuta K et al. Green tea polyphenol epigallocatechin-3-gallate blocks PDGF-induced proliferation and migration of rat pancreatic stellate cells. *World J Gastroenterol* . 2005;11(22):3368-74.
- McBride G. Screening methods may offer early diagnosis of pancreatic cancer. *J Natl Cancer Inst* 2004;96(21):1571.
- McIntyre BS, Sylvester PW. Genistein and erbstatin inhibition of normal mammary epithelial cell proliferation is associated with EGF-receptor down-regulation. *Cell Prolif* . 1998;31(1):35-46.
- McKenna WG, Muschel RJ. Targeting tumor cells by enhancing radiation sensitivity. *Genes Chromosomes Cancer* . 2003;38(4):330-8.
- Merendino N, Molinari R et al. Induction of apoptosis in human pancreatic cancer cells by docosahexaenoic acid. *Ann N Y Acad Sci* . 2003;1010:361-4.
- Michaud DS. Epidemiology of pancreatic cancer. *Minerva Chir* . 2004;59(2):99-111.
- Michaud DS, Liu S et al. Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. *J Natl Cancer Inst* . 2002;94(17):1293-300.
- Milella M, Gelibter A et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. *Cancer* . 2004;101(1):133-8.
- Miltyk W, Craciunescu CN et al. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. *Am J Clin Nutr* . 2003;77(4):875-82.
- Missiaglia E, Donadelli M et al. Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway. *Oncogene* . 2005;24(1):199-211.
- Modrak DE, Cardillo TM et al. Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer. *Cancer Res* . 2004;64(22):8405-10.
- Moniaux N, Varshney GC et al. Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans. *J Histochem Cytochem* . 2004;52(2):253-61.
- Moore PS, Beghelli S et al. Genetic abnormalities in pancreatic cancer. *Mol Cancer* . 2003;2(1):7.
- Morgan-Meadows S, Dubey S et al. Phase I trial of perillyl alcohol administered four times daily continuously. *Cancer Chemother Pharmacol* . 2003;52(5):361-6.
- Moses AW, Slater C et al. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can

be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. *Br J Cancer* . 2004;90(5):996-1002.

Naderi A, Couch FJ. BRCA2 and pancreatic cancer. *Int J Gastrointest Cancer* . 2002;31(1-3):99-106.

Naidu KA, Karl RC et al. Antiproliferative and proapoptotic effect of ascorbyl stearate in human pancreatic cancer cells: association with decreased expression of insulin-like growth factor 1 receptor. *Dig Dis Sci* . 2003;48(1):230-7.

Nakamura T, Takebe K et al. Effects of pancreatic digestive enzymes, sodium bicarbonate, and a proton pump inhibitor on steatorrhoea caused by pancreatic diseases. *J Int Med Res* . 1995;23(1):37-47.

Needle MN. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. *Semin Oncol* . 2002;29(5 Suppl 14):55-60.

Nishikawa A, Furukawa F et al. Potent chemopreventive agents against pancreatic cancer. *Curr Cancer Drug Targets* . 2004;4(4):373-84.

Noguchi K, Tanimura H et al. Polysaccharide preparation PSK augments the proliferation and cytotoxicity of tumor-infiltrating lymphocytes in vitro. *Anticancer Res* . 1995;15(2):255-8.

Novak JF, Trnka F. Proenzyme therapy of cancer. *Anticancer Res* . 2005;25(2A):1157-77.

Ochi K, Harada H et al. Intraductal secretin test is as useful as duodenal secretin test in assessing exocrine pancreatic function. *Dig Dis Sci* . 1997;42(3):492-596.

Ohta T, Arakawa H et al. [A new strategy for the therapy of pancreatic cancer by proton pump inhibitor]. *Gan To Kagaku Ryoho* . 1996;23(12):1660-4.

Ohwada S, Ikeya T et al. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. *Br J Cancer* . 2004;90(5):1003-10.

Oki Y, Younes A. Heat shock protein-based cancer vaccines. *Expert Rev Vaccines* . 2004;3(4):403-11.

Owen RW, Haubner R et al. Olives and olive oil in cancer prevention. *Eur J Cancer Prev* . 2004;13(4):319-26.

Pares A, Planas R et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. *J Hepatol* . 1998;28(4):615-21.

Perez MM, Newcomer AD et al. Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer. *Cancer* . 1983;52(2):346-52.

Persson C, Glimelius B et al. Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study. *Nutrition* . 2005;21(2):170-8.

Pezzilli R. Screening tests for pancreatic cancer: searching for the early symptoms or the population at risk. *Jop* 2004;5(4):240-2.

Prasad AS, Bao B et al. Antioxidant effect of zinc in humans. *Free Radic Biol Med* . 2004;37(8):1182-90.

Qanungo S, Das M et al. Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. *Carcinogenesis* . 2005;26(5):958-67.

Rautalahti MT, Virtamo JR et al. The effects of supplementation with alpha-tocopherol and beta-carotene on the incidence and mortality of carcinoma of the pancreas in a randomized, controlled trial. *Cancer* . 1999;86(1):37-42.

Ravichandran D, Cooper A et al. Growth inhibitory effect of lithium gammalinolenate on pancreatic cancer cell lines: the influence of albumin and iron. *European Journal of Cancer* . 1998;34(1):188-92.

Rayes N, Hansen S et al. Early enteral supply of fiber and Lactobacilli versus conventional nutrition: a controlled trial in patients with major abdominal surgery. *Nutrition* . 2002;18(7-8):609-15.

Recchia F, Sica G et al. Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and

retinoids. *Am J Clin Oncol* . 1998;21(3):275-8.

Rich TA, Shepard R. COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas. *Am J Clin Oncol* . 2004;26(4):S110-S113.

Ripple GH, Gould MN et al. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. *Clin Cancer Res* 2000 Feb;6(2):390-6 . 2000;6(2):390-6.

Robles-Diaz G, Duarte-Rojo A. Pancreas: a sex steroid-dependent tissue. *Isr Med Assoc J* . 2001;3(5):364-8.

Roomi MW, Ivanov V et al. Antitumor effect of a combination of lysine, proline, arginine, ascorbic acid, and green tea extract on pancreatic cancer cell line MIA PaCa-2. *Int J Gastrointest Cancer* . 2005;35(2):97-102.

Rosenstein ED, Kushner LJ et al. Pilot study of dietary fatty acid supplementation in the treatment of adult periodontitis. *Prostaglandins Leukot Essent Fatty Acids* . 2003;68(3):213-8.

Rulyak SJ, Brentnall TA. Inherited pancreatic cancer: improvements in our understanding of genetics and screening. *Int J Biochem Cell Biol* 2004;36(8):1386-92.

Rulyak SJ, Lowenfels AB et al. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. *Gastroenterology* . 2003;124(5):1292-9.

Safran H, Iannitti D et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. *Cancer Invest* . 2004;22(5):706-12.

Saisho H, Yamaguchi T. Diagnostic imaging for pancreatic cancer: computed tomography, magnetic resonance imaging, and positron emission tomography. *Pancreas* . 2004;28(3):273-8.

Saitou M, Goto M et al. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. *J Clin Pathol* . 2005;58(8):845-52.

Sangro B, Mazzolini G et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. *J Clin Oncol* . 2004;22(8):1389-97.

Saruc M, Standop S et al. Pancreatic enzyme extract improves survival in murine pancreatic cancer. *Pancreas* . 2004;28(4):401-12.

Sato T, Odagiri H et al. Chemosensitivity of human pancreatic carcinoma cells is enhanced by IkappaBalpha super-repressor. *Cancer Sci* . 2003;94(5):467-72.

Schibli S, Durie PR et al. Proper usage of pancreatic enzymes. *Curr Opin Pulm Med* . 2002;8(6):542-6.

Schima W, Fugger R et al. Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT. *AJR American Journal of Roentgenology* . 2002;179(3):717-24.

Schusdziarra V, Holland A et al. Effect of naloxone on pancreatic and gastric endocrine function in response to carbohydrate and fat-rich test meals. *Peptides* . 1984;5(1):65-71.

Shi Y, Wu J et al. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival. *Prostate* . 2005;62(1):69-82.

Shiraishi K, Okita K et al. A comparison of DNA copy number changes detected by comparative genomic hybridization in malignancies of the liver, biliary tract and pancreas. *Oncology* . 2001;60(2):151-61.

Simon B, Printz H. Epidemiological trends in pancreatic neoplasias. *Dig Dis* . 2001;19(1):6-14.

Singh AP, Moniaux N et al. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. *Cancer Res* . 2004;64(2):622-30.

Singh J, Hamid R et al. Dietary fat and colon cancer: Modulating effect of types and amount of dietary fat on ras-p21 function during

promotion and progression stages of colon cancer. *Cancer Res* . 1997;57(2):253-8.

Singh SV. Impact of garlic organosulfides on p21(H-ras) processing. *J Nutr* . 2001;131(3S):1046S-8S.

Snady H, Bruckner HW et al. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. *Cancer* . 2000;89(2):314-27.

Sohma M, Kitagawa T et al. [Two cases of unresectable pancreatic cancer responding to combined chemotherapy with cisplatin, PSK and UFT]. *Gan To Kagaku Ryoho* . 1987;14(6 Pt 1):1926-9.

Sonwalkar SA, Holbrook IB et al. A prospective, comparative study of the para-aminobenzoic acid test and faecal elastase 1 in the assessment of exocrine pancreatic function. *Aliment Pharmacol Ther* . 2003;17(3):467-71.

Stark MJ, Burke YD et al. Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol. *Cancer Lett* . 1995;96(1):15-21.

Stephens FO. The increased incidence of cancer of the pancreas: Is there a missing dietary factor? Can it be reversed? *Aust N Z J Surg* . 1999;69(5):331-5.

Stolzenberg-Solomon RZ, Pietinen P et al. Dietary and other methyl-group availability factors and pancreatic cancer risk in a cohort of male smokers. *American Journal of Epidemiology* . 2001;153(7):680-7.

Suzuki K, Aiura K et al. Platelets counts closely correlate with the disease-free survival interval of pancreatic cancer patients. *Hepatology* . 2004;51(5):847-53.

Takada M, Nakamura Y et al. Suppression of human pancreatic carcinoma cell growth and invasion by epigallocatechin-3-gallate. *Pancreas* . 2002;25(1):45-8.

Takimoto CH, Glover K et al. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. *Cancer Epidemiol Biomarkers Prev* . 2003;12(11 Pt 1):1213-21.

Thies F, Miles EA et al. Influence of dietary supplementation with long-chain n-3 or n-6 polyunsaturated fatty acids on blood inflammatory cell populations and functions and on plasma soluble adhesion molecules in healthy adults. *Lipids* . 2001;36(11):1183-93.

Tisdale MJ. Wasting in cancer. *J Nutr* . 1999;129(1S Suppl):243S-6S.

Toge T, Yamaguchi Y. Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count. *Oncol Rep* . 2000;7(5):1157-61.

Tong WG, Ding XZ et al. Lipoxigenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. *Mol Cancer Ther* . 2002;1(11):929-35.

Truninger K. [Risk groups for pancreatic and bile duct carcinomas]. *Schweiz Rundsch Med Prax* . 2000;89(33):1299-304.

Tsai AC, Vinik AI et al. Effects of soy polysaccharide on postprandial plasma glucose, insulin, glucagon, pancreatic polypeptide, somatostatin, and triglyceride in obese diabetic patients. *Am J Clin Nutr* . 1987;45(3):596-601.

Tseng WW, Deganutti A et al. Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. *J Gastrointest Surg* . 2002;6(6):838-43.

Tsukagoshi S, Hashimoto Y et al. Krestin (PSK). *Cancer Treat Rev* . 1984;11(2):131-55.

Tucker ON, Dannenberg AJ et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. *Cancer Res* . 1999;59(5):987-90.

Uden S, Schofield D et al. Antioxidant therapy for recurrent pancreatitis: biochemical profiles in a placebo-controlled trial. *Aliment Pharmacol Ther* . 1992;6(2):229-40.

Vaquero EC, Edderkaoui M et al. Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer

cells. *J Biol Chem* . 2004;279(33):34643-54.

Vigushin DM, Poon GK et al. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. *Cancer Chemother Pharmacol* . 1998;42(2):111-7.

Way TD, Kao MC et al. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. *J Biol Chem* . 2004;279(6):4479-89.

Wei D, Wang L et al. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. *Cancer Res* . 2004;64(6):2030-8.

Wenger FA, Kilian M et al. Influence of antioxidative vitamins A, C and E on lipid peroxidation in BOP-induced pancreatic cancer in Syrian hamsters. *Prostaglandins Leukotrienes & Essential Fatty Acids* . 2001;65(3):165-71.

Weydert C, Roling B et al. Suppression of the malignant phenotype in human pancreatic cancer cells by the overexpression of manganese superoxide dismutase. *Mol Cancer Ther* . 2003;2(4):361-9.

Whitehouse PA, Cooper AJ et al. Synergistic activity of gamma-linolenic acid and cytotoxic drugs against pancreatic adenocarcinoma cell lines. *Pancreatology* . 2003;3(5):367-73.

Wiedmann MW, Caca K. Molecularly targeted therapy for gastrointestinal cancer. *Curr Cancer Drug Targets* . 2005;5(3):171-93.

Wigmore SJ, Barber MD et al. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. *Nutrition & Cancer* . 2000;36(2):177-84.

Wigmore SJ, Ross JA et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. *Nutrition* . 1996;12(1 Suppl):27-30.

Wilentz RE, Chung CH et al. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. *Cancer* . 1998 Jan 1;82(1):96-103.

Wilson LC, Baek SJ et al. Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells. *Int J Cancer* . 2003;105(6):747-53.

Woutersen RA, Appel MJ et al. Modulation of pancreatic carcinogenesis by antioxidants. *Food Chem Toxicol* . 1999;39(9-10):981-4.

Xiong HQ, Rosenberg A et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. *J Clin Oncol* . 2004a;22(13):2610-6.

Xiong HQ, Rosenberg A et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. *J Clin Oncol* . 2004b;22(13):2610-6.

Yamaguchi K, Nakamura K et al. Intraoperative radiation enhances decline of pancreatic exocrine function after pancreatic head resection. *Dig Dis Sci* . 2000;45(6):1084-90.

Yamao K, Okubo K et al. Endolumenal ultrasonography in the diagnosis of pancreatic diseases. *Abdom Imaging* . 2003;28(4):545-55.

Yang XD, Jia XC et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. *Crit Rev Oncol Hematol* . 2001;38(1):17-23.

Yokoe T, Iino Y et al. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK. *Anticancer Res* . 1997;17(4A):2815-8.

Zemskov V, Prokopchuk O et al. Efficacy of ukrain in the treatment of pancreatic cancer. *Langenbecks Arch Surg* . 2002;387(2):84-9.

Zhan CD, Sindhu RK et al. Superoxide dismutase, catalase and glutathione peroxidase in the spontaneously hypertensive rat kidney: effect of antioxidant-rich diet. *J Hypertens* . 2004;22(10):2025-33.

Zhang H, Morisaki T et al. Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs. *Clin Exp Metastasis* . 2000;18(4):343-52.

Zhang H, Morisaki T et al. PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. *Oncogene* . 2003;22(14):2088-96.

Zullo A, Rinaldi V et al. Ascorbic acid and intestinal metaplasia in the stomach: a prospective, randomized study. *Aliment Pharmacol Ther* . 2000;14(10):1303-9.

All Contents Copyright © 1995-2009 Life Extension Foundation All rights reserved.

LifeExtension®

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.